Abstract Library

#4548 Carcinoid heart disease in patients with carcinoid syndrome and metastatic small intestinal neuroendocrine tumours: A single centre experience

Introduction: Carcinoid heart disease (CHD) is a significant complication of carcinoid syndrome (CS) in patients with small intestinal neuroendocrine tumours (SINET). Management is complex and more data is needed.

Conference:

Presenting Author:

Authors: Salman M, Waters M, Abbott C, Quinn M, O'Toole D,

Keywords: carcinoid heart disease, carcinoid syndrome, NET, neuroendocrine tumour, small intestinal NET,

#3893 Pancreatic neuroendocrine tumor associated hypophosphatemia due to tumor-induced osteomalacia – A case report

Introduction: Tumor-induced osteomalacia (TIO) is a rare syndrome characterised by hypophosphataemia and osteomalacia with renal phosphate wasting caused by elevated levels of fibroblast growth factor 23 (FGF23) in the setting of tumor. The primary tumor is typically found in bone or soft tissue.

Conference:

Presenting Author:

Authors: Storan D, Almeamar H, O'Shea D, O'Toole D, Crowley R,

Keywords: pNET, pancreas, hypophosphataemia, osteomalacia, fgf23,

#3825 Ga-68 DOTA-TOC PET/CT uptake by the parathyroid glands in patients with multiple endocrine neoplasia type 1 (MEN1)

Introduction: Primary hyperparathyroidism (PHPT) is the most common manifestation of MEN1. While Ga-68 DOTA-TOC PET/CT (GaPET) is increasingly used in this cohort for assessment of neuroendocrine tumors (NETs), there are limited data on its utility in assessing parathyroid disease.

Conference:

Presenting Author: Storan D

Authors: Storan D, Flynn S, O'Toole D, Almeamar H, O'Shea D,

Keywords: MEN1, PET CT, Gallium, Parathyroid,

#3579 Setting up of a national liver transplant programme for neuroendocrine tumor liver metastases in UK and Ireland: Opportunities for collaborations in clinical study and research

Introduction: Liver transplantation [LT] for unresectable neuroendocrine tumor liver metastases [NET LM] is one of three new cancer indications in UK and Ireland. Transplant benefit is only proven using the Milan criteria so patient selection needs to be meticulously objective. We have therefore created a national MDT to provide a formal framework, aid patient selection, oversee data collection, monitor performance, provide training and education, deliver equity of access, facilitate research and clinical trials.

Conference:

Presenting Author:

Authors: Shah T, Gibbs P, Moore J, Venkataraman H, O'Toole D,

Keywords: liver transplantation, neuroendocrine tumor liver metastasis, neuroendocrine tumor surgery,

#3560 Nutritional status in patients with neuroendocrine tumors: A single ENETS Centre of Excellence experience

Introduction: Studies show that 14–68% of patients with neuroendocrine tumors (NETS) are at risk of or are malnourished. Patients’ dependent on NET type, primary or treatment are at risk of Vitamin B12, A, D E, iron deficiencies, pancreatic enzyme insufficiency (PEI) and a high HbA1c.

Conference:

Presenting Author:

Authors: Burke D, Almeamar H, O'Toole D, Barnes L, Crowley R,

Keywords: malnutrition, deficiencies, Pancreatic enzyme insufficiency, HbA1c's,